Is It Better To Be First Or Best? Daiichi Sankyo Shifts R&D Priorities
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Daiichi Sankyo's R&D leaders are optimistic about how the Factor Xa inhibitor edoxaban can compete in a potentially crowded market, but the company is also shifting its focus to development of first-in-class compounds, citing commercial and regulatory hurdles for follow-on, best-in-class products.
You may also be interested in...
ROCKET AF: Positive Results For Xarelto, But A Few Chinks In The Armor
Rivaroxaban misses two bleeding safety measures, and debate heats up on whether it showed superior efficacy against warfarin.
Daiichi Sankyo's Factor Xa Bests Enoxaparin In Phase III Trial For VTE
TOKYO - Daiichi Sankyo announced July 12 its factor Xa inhibitor edoxaban posted superior results to Sanofi-Aventis' Lovenox (enoxaparin), a low dose heparin, in preventing venous thromboembolic events in patients following total knee replacement. The announcement will put Daiichi Sankyo's marketing chops to the test, as the compound, while clear in its efficacy, is primed to enter a market with a number of potential factor Xa competitors in a Japanese antithrombotic market still dominated by heparin and warfarin
Japanese Pharmas Hit By Strong Yen: Japanese Pharma Earnings Roundup
TOKYO - As expected, top Japanese pharmaceutical players have reported lackluster April-June earnings as they struggled under the strong yen's weight, with three leading firms reiterating efforts to expedite launching products now in the pipelines